Meta-analysisindependent cross-checkabstract checked I-SUP-118 standard review

Glucosamine for knee and hip arthritis

Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank.

Overview

Runhaar J et al.. Ann Rheum Dis 2017 · PMID 28754801 · DOI 10.1136/annrheumdis-2017-211149

Using raw data from five independent trials, glucosamine was no better than a dummy pill for pain or function.

Does the study support the specific claim? Yes · Methodological quality: high

Original publication

Plain-language summary

Study explained simply

What did the researchers want to find out?: To test glucosamine in osteoarthritis subgroups.
How was the study done?: Individual patient data meta-analysis.
How many people, animals or samples were studied?: 1,625 patients in placebo trials.
What was actually found?: No benefit overall or in any subgroup.
How large was the observed effect?: Not given.
What do the results mean in everyday life?: Glucosamine is unlikely to help arthritis pain.
What are the study's limitations?: Not all trials shared data.
What does it say about Elawady's specific claim?: Supports C-SUP-07 and C-SUP-01.
Do the results apply to Germany and Europe?: Applicable.
What can explicitly not be concluded from this study?: Cannot rule out effects of specific products.

Scientific in-depth review

1. Full reference

Authors: Runhaar J et al.
Journal: Ann Rheum Dis
Year: 2017
Identifier: PMID 28754801 DOI 10.1136/annrheumdis-2017-211149
Verification: verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: COI statement in record: Competing interests: None declared.; funding listed: Department of Health

2. Research question

Is oral glucosamine effective for hip or knee osteoarthritis, overall and in subgroups?

3. Study design and population

Study design: Meta-analysis – Systematic review and individual patient data meta-analysis (OA Trial Bank)
Population: People with hip or knee osteoarthritis
Country: Multinational
Period: Not stated in abstract
Sample size: 6 trials shared data (n=1,663); 5 placebo-controlled (n=1,625)
Inclusion and exclusion criteria: RCTs of oral glucosamine in clinically/radiographically defined OA

4. Methods and endpoints

Exposure / intervention: Oral glucosamine
Comparator: Placebo
Endpoints: Pain and function at 3 and 24 months
Statistical methods: IPD meta-analysis with subgroups

5. Actual results

Results: Glucosamine was no better than placebo for pain or function at 3 and 24 months, overall and in predefined subgroups (pain severity, BMI, sex, structural abnormalities, inflammation). The 5 placebo trials were all industry-independent and represented 55% of participants in published placebo-controlled RCTs.
Absolute risks: not reported in abstract
Authors' conclusion: No good evidence supports glucosamine for hip or knee OA, nor for any clinically relevant subgroup.

6. Strengths

Individual patient data
Industry-independent trials

7. Weaknesses

Only 6 of 21 eligible trials shared data
Industry trials not included (may differ)

8. Risk of bias

Orienting tool: AMSTAR 2
Type of assessment: simplified assessment (abstract only)
Full formal assessment: no
Overall risk of bias: some concerns
Rationale: Data availability bias possible.

9. Assessment of the statistical interpretation

No numerical estimates in abstract.

10. Relevance to the specific claim

Supports the claim that glucosamine does not relieve knee pain.

11. Independent contrary findings

Some industry-sponsored trials reported benefit.

12. Transferability to Germany and Europe

Applicable.

13. Overall methodological judgement

Strong support for 'no benefit' of glucosamine.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	high
Risk of bias	some concerns
Precision of results	moderate
Directness	direct
Reproducibility	replicated
Consistency with the overall evidence	consistent
Regional transferability	high
Adequacy of the interpretation (by the archive)	not applicable

14. Open questions

Results of non-shared industry trials.